TuHURA Biosciences' (HURA) "Sell (E+)" Rating Reaffirmed at Weiss Ratings

Key Points

• TuHURA Biosciences (HURA) received a "sell (E+)" rating reaffirmed by Weiss Ratings, while other analysts have varying ratings from "hold" to "strong-buy" for the stock.
• The stock currently trades at $2.61, significantly lower than its twelve-month high of $8.40, and has a reported earnings miss for the last quarter of ($0.21) EPS.
• Recent activity indicates increased interest from institutional investors, with several funds acquiring new positions in TuHURA Biosciences during the second quarter.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report)'s stock had its "sell (e+)" rating reissued by stock analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

HURA has been the topic of several other reports. Wall Street Zen upgraded shares of TuHURA Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. Brookline Capital Management upgraded shares of TuHURA Biosciences to a "strong-buy" rating in a report on Monday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $12.67.

TuHURA Biosciences Trading Up 4.4%

HURA opened at $2.61 on Wednesday. The firm's fifty day moving average is $2.65 and its two-hundred day moving average is $3.01. TuHURA Biosciences has a twelve month low of $1.80 and a twelve month high of $8.40.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07).

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of TuHURA Biosciences during the second quarter worth $31,000. Merck & Co. Inc. bought a new position in TuHURA Biosciences in the second quarter valued at $31,000. Marshall Wace LLP bought a new position in TuHURA Biosciences in the second quarter valued at $79,000. Invesco Ltd. bought a new position in TuHURA Biosciences in the second quarter valued at $30,000. Finally, New York State Common Retirement Fund bought a new position in TuHURA Biosciences in the second quarter valued at $97,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.